An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
Collaboration with Ned Laudau's Lab at NYU developing new SARS-CoV-2 antivirals. (https://pubmed.ncbi.nlm.nih.gov/33326798/)
The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
Collaboration with Shohei Koide's Lab at NYU looking at SARS-CoV-2 antibody interactions. (https://pubmed.ncbi.nlm.nih.gov/33310017/)
Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
Collaboration with Chuan-Ju Liu's Lab at NYU screening FDA-approved compounds against SARS-CoV-2. (https://pubmed.ncbi.nlm.nih.gov/33210243/)
Chikungunya virus antagonizes cGAS-STING mediated type-I interferon responses by degrading cGAS
Collaboration with the Fernandez-Sesma Lab at Mt. Sinai to understand how CHIKV antagonizes the innate immune response.
Distinct New York City Aedes albopictus Mosquito Populations Display Differences in Salivary Gland Protein D7 Diversity and Chikungunya Virus Replication
Maryska characterizes antiviral factors and CHIKV replication and evolution in New York City mosquitoes! (https://pubmed.ncbi.nlm.nih.gov/32605312/)
Evolution-driven attenuation of alphaviruses highlights key glycoprotein determinants regulating viral infectivity and dissemination
First Stapleford Lab CHIKV dissemination paper! Gaby, Bruno, and Margarita identify a network of molecular interactions that modulate CHIKV infectivity and dissemination. (https://www.ncbi.nlm.nih.gov/pubmed/31291581)
Chikungunya virus vaccine candidates with decreased mutational robustness are attenuated in vivo and have compromised transmissibility.
Collaboration with the Vignuzzi lab at Institut Pasteur, Paris, to develop novel vaccine strategies for arboviruses. (https://www.ncbi.nlm.nih.gov/pubmed/31270226)
Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides.
First paper from the Stapleford Lab! Angelica Kottkamp defines the antiviral mechanism of the antiparasitic drug atovaquone. (https://www.ncbi.nlm.nih.gov/pubmed/30894466)
Chikungunya virus evolution following a large 3'UTR deletion results in host-specific molecular changes in protein-coding regions.
Collaboration with Paul Turner's lab at Yale University to understand the evolution of the chikungunya virus 3'UTR. (https://www.ncbi.nlm.nih.gov/pubmed/29942653)